IP Library Granted Patent US 9,206,455
Granted Patent B2
US 9,206,455 · App. 13/779,952 · Granted Dec 8, 2015

Fucosylation-deficient cells

Inventors: Gang Chen (Yorktown Heights, NY); Darya Burakov (Yonkers, NY); James P. Fandl (LaGrangeville, NY)
Assignee: REGENERON PHARMACEUTICALS, INC.
C12P21/005C07K16/00C07K16/2863C07K16/2866C12N9/0006C12N15/00C07K2317/14C07K2317/41
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,206,455
App. No.
13/779,952
Granted
Dec 8, 2015
Kind
B2
Abstract

An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.

Claims (12)

1. A cell capable of fucosylating a glycoprotein, wherein the cell comprises a nucleic acid encoding a modified GDP-4-keto-6-deoxy-mannose-3,5-epimerase-4-reductase (FX) protein consisting of SEQ ID NO:1 except having an amino acid modification serine at position 289 (289S), and wherein no more than about 10% of the glycoprotein is fucosylated when the cell is grown at a temperature of about 37° C. in the absence of an external fucose source.

2. The cell of claim 1 , wherein the cell is a Chinese hamster ovary (CHO) cell.

3. The cell of claim 1 , wherein the glycoprotein comprises an immunoglobulin CH2 region and an immunoglobulin CH3 region.

4. The cell of claim 3 , wherein the glycoprotein is an antibody.

5. The cell of claim 3 , wherein no more than about 6% of the glycoprotein is fucosylated when the cell is grown at a temperature of about 37° C. in the absence of an external fucose source.

6. The cell of claim 5 , wherein no more than about 2% of the glycoprotein is fucosylated when the cell is grown at a temperature of about 37° C. in the absence of an external fucose source.

7. The cell of claim 1 , wherein the cell fucosylates at least 70% of the glycoprotein when the cell is grown at a temperature of about 34° C. in the absence of an external fucose source.

8. The cell of claim 1 , wherein the cell fucosylates at least 90% of the glycoprotein when the cell is grown at a temperature of about 34° C. in the absence of an external fucose source.

9. The cell of claim 1 , wherein the cell fucosylates at least 70% of the glycoprotein when the cell is grown at a temperature of about 37° C. in the presence of an external fucose source.

10. The cell of claim 1 , wherein the cell fucosylates at least 90% of the glycoprotein when the cell is grown at a temperature of about 37° C. in the presence of an external fucose source.

11. The cell of claim 1 , wherein the cell further comprises at least one nucleic acid encoding an immunoglobulin protein.

12. An isolated nucleic acid encoding a modified GDP-4-keto-6-deoxy-mannose-3,5-epimerase-4-reductase (FX) protein consisting of SEQ ID NO:1 except having an amino acid modification serine at position 289 (289S).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2013
From: CHEN, GANG; BURAKOV, DARYA; FANDL, JAMES P.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 030409/0406 →
Continuity (4)
Division 12791637 · Jun 1, 2010
Provisional Application 61348858 · May 27, 2010
Provisional Application 61183400 · Jun 2, 2009
Related Publication 20130164786A1 · Jun 27, 2013